内科学进展 4造血干细胞移植术.ppt.pptVIP

* Analyses of overall survival were performed on all patients randomized to treatment. After discontinuation of study treatment, all patients were followed for survival until death or loss to follow-up. Analysis of survival was performed using the Kaplan-Meier method based on the intent-to-treat (ITT) principle using all data available, regardless of whether crossover occurred These analyses therefore include deaths that occurred after discontinuation of treatment. There were a total of 57 deaths in patients randomized to imatinib: 14 deaths after BMT, 23 due to CML, and 20 un-related to CML. Overall estimated survival at 60 months was 89%. When the analysis was censored for deaths related to CML, the overall survival was estimated to be 95% * Therapy with imatinib continues to be generally well tolerated, and demonstrates excellent efficacy and durable responses High rates of response to imatinib continue to improve with time 5-year overall survival is 89% (95% with censor of non-CML and SCT-related deaths) Onset of grade 3 /4 toxicity decreased over time Annual rates of progression (event-free and to AP/BC) decline with time CCyR and MMR associated with prolonged survival CCyR overcomes high-risk pre-therapeutic Sokal score No new safety concerns were observed over time * * * * * * * * Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase Reuven Or, Michael Y. Shapira, Igor Resnick, Avraham Amar, Aliza Ackerstein, Simcha Samuel, Memet Aker, Elizabeth Naparstek, Arnon Nagler, and Shimon Slavin From the Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Hospital, Jerusalem, Israel; the Tissue Typing Department, Hadassah-Hebrew University Hospital, Jerusalem, Israel; and the Department of Pediatrics, Hadassah-Hebrew University Hospital, Jerusalem, Israel. Figure 1. Kaplan-Meier actuarial survival and disease-free survival of patients with CML i